In Vivo Modulation of Macrophage Tumoricidal Activity by Oral Administration of the Liposome-encapsulated Macrophage Activator CGP 19835A

Cancer Research

Volumn 54, Issue 22, 1994, Pages 5882-5888

  Tanguay, Simon ^a   Bucana, Corazon D ^a   Wilson, Michael R ^a   Fidler, Isaiah J ^a   von Eschenbach, Andrew C ^a   KiIlion, Jerald J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 6; LIPOSOME; MURAMYL TRIPEPTIDE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NITRIC OXIDE; PHOSPHATIDYLCHOLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOMODULATION; KIDNEY CARCINOMA; LUNG ALVEOLUS MACROPHAGE; LUNG METASTASIS; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN DISTRIBUTION; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; DRUG CARRIERS; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-1; INTERLEUKIN-6; KIDNEY NEOPLASMS; LIPOSOMES; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; PHOSPHATIDYLETHANOLAMINES; SPECIFIC PATHOGEN-FREE ORGANISMS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0027939443     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Fidler, I. J., Sone, S., Fogler, W. E., Smith, D., Braun, D. G., Tarcsay, L., Gisler, R. R., and Schroit, A. J., Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J. Biol. Response Modif. 1: 43-55, 1982.
2. Kleinerman, E. S., Erickson, K. L., Schroit, A. J., Fogler, W. E., and Fidler, I. J., Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 43: 2010-2014, 1983.
3. Utsugi, T., Nii, A. Fan, D., Pak, C. C., Denkins, Y., van Hoogevest, P., and Fidler, I. J., Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Immunol. Immunother. 33: 285-292, 1991.
4. Fidler, I. J., and Schroit, A J. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases. J. Immunol. 133: 515-518, 1984.
5. Utsugi, T., Dinney, C.P.N. Killion, J. J., and Fidler, I. J., In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Cancer Immunol. Immunother. 33: 375-381, 1991.
6. Fidler, I. J., Optimization and limitations of systemic treatment of murine melanoma metastasis with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol. Immunother. 21: 169-173, 1986.
7. Fidler, I. J., Sone, S., Fogler, W. E., and Barnes, Z. L., Eradication of spontaneous metastasis and activation of alveolar macrophages by intravenous injection of liposome containing muramyl dipeptide. Proc. Natl. Acad. Sci. USA 78: 1680-1684, 1981.
8. Dinney, C.P.N. Utsugi, T., Fidler, I. J., von Eschenbach, A. C., and Killion, J. J., Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or γ-interferon. Cancer Res. 52: 1155-1161, 1992.
9. MacEwen, E. G., Kurzman, I. D., Rosenthal, R. C., Smith, B. W., Manley, P. A., Roush, J. K., and Howard, P. E., Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl. Cancer Inst. 81: 935-938, 1989.
10. Asano, T., and Kleinerman, E. S., Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J. Immunother. 14: 286-292, 1993.
11. Kleinerman, E. S., Jia, S. F., Griffin, J., Seibel, N. L., Benjamin, R. S., and Jaffe, N., Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J. Clin. Oncol. 10: 1310-1316, 1992.
12. Kleinerman, E. S., Raymond, A. K., Bucana, C. D., Jaffe, N., Harris, M. B., Krakoff, I. H., Benjamin, R., and Fidler, I. J., Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol. Immunother. 34: 211-220, 1992.
13. Fidler, I. J., Fogler, W. E., Brownbill, A. F., and Schumann, G., Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J. Immunol. 138: 4509-4514, 1987.
14. Schroit, A. J., and Fidler, I. J., Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 42: 161-167, 1982.
15. Murphy, C. G., and Hrushesky, W. J., A murine renal cell carcinoma. J. Natl. Cancer Inst. 50: 1013-1025, 1973.
16. Struck, D. K., and Pagano, R. E., Insertion of fluorescent phospholipids into the plasma membrane of a mammalian cell. J. Biol. Chem. 755: 5405-5410, 1981.
17. Raz, A., Fogler, W. E., and Fidler, I. J., The effects of experimental conditions on the expression of in vitro mediated tumor cytotoxicity by murine macrophages. Cancer Immunol. Immunother. 7: 157-163, 1979.
18. Saiki, I., and Fidler, I. J., Synergistic activation by recombinant mouse interferon-γ and muramyl dipeptide of tumoricidal properties in mouse macrophages. J. Immunol. 135: 684-688, 1985.
19. Fidler, I. J., Nii, A., Utsugi, T. Brown, D., Bakouche, O., and Kleinerman, E. S., Differential release of TNF-a, IL-1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Lymphokine Res. 9: 449-463, 1990.
20. Fogler, W. E., and Fidler, I. J., Modulation of the immune response by muramyl dipeptide. In: M.A. Chirigos and R.L. Fenichel (eds.), Immune Modulation Agents and Their Mechanisms, p. 499. New York: Marcel Dekker, Inc. 1984.
21. Meager, A., RIA, IRMA, and ELISA assays for cytokines. In: F. Balkwill (ed.), Cytokines: A Practical Approach, pp. 299-307. Oxford, United Kingdom: IRL Press, Ltd. 1991.
22. Ding, A. H., Nathan, C. F., and Stuehr, D. J., Release of reactive nitrogen intermediate and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141: 2407-2411, 1988.
23. Maeda, M., Knowles, R. D., and Kleinerman, E. S., Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun. 3: 313-321, 1991.
24. Bakouche, O., Koff, W. C., Brown, D. C., and Lachman, L. B., Interleukin 1 release by human monocytes treated with liposome-encapsulated lipopolysaccharide. J. Immunol. 139: 1120-1126, 1987.
25. Wollenberg, G. K., DeForge, L. E., Bolgos, G., and Remick, D. G., Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am. J. Pathol. 143: 1121-1130, 1993.
26. Poste, G., Bucana, C. Raz, A., Bugelski, P. Kirsh, R., and Fidler, I. J., Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 42: 1412-1422, 1982.
27. Fidler, I. J., Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv. Drug Delivery Rev. 2: 69-106, 1988.
28. Utsugi, T., Dinney, C. P., Killion, J. J., Brown, D., and Fidler, I. J., In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells. Lymphokine Cytokine Res. 10: 487-493, 1991.
29. Singh, R. K., and Fidler, I. J., Synergism between human recombinant monocyte chemotactic and activating factor and lipopolysaccharide for activation of antitumor properties in human blood monocytes. Lymphokine Cytokine Res. 12: 285-291, 1993.
30. Nii, A., Utsugi, T. Fan, D., Denkins, Y. Pak, C., Brown, D., van Hoogevest, P., and Fidler, I. J., Optimization of the liposomes encapsulating a new lipopeptide CGP 31362 for efficient activation of tumoricidal properties in monocytes and macrophages. J. Immunother. 10: 236-246, 1991.
31. Hibbs, J. B., Jr. Taintor, R. R., Vavrin, Z., and Rachlin, E. M., Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157: 87-94, 1988.
32. Stuerh, D. J., and Nathan, C. F., Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169: 1534-1545, 1989.
33. Ruedl, C., Albin, B. Bock, G., Wick, G., and Wolf, H., Oral administration of a bacterial immunomodulator enhances murine intestinal lamina propria and Peyer's patch lymphocyte traffic to the lung: possible implications for infectious disease prophylaxis and therapy. Int. Immunol. 5: 29-36, 1993.